ArticleThe British journal of cardiology2024
AV nodal ablation, where are we now? Insight from real-world Northern Irish multi-centre registry data.
Article in The British journal of cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrioventricular nodal (AVN) ablation with permanent pacemaker implantation - 'pace and ablate' - may be considered for patients with symptomatic atrial fibrillation (AF) for whom rhythm control has been unsuccessful. This creates concerns about inducing pacemaker dependence and potential pacemaker-induced cardiomyopathy (PICM). Conduction-system pacing mitigates PICM, so we expect a greater uptake of AVN ablation going forward. We conducted a retrospective multicentre review of our patients who underwent AVN ablation over a one-year period. AVN ablation was successful with durable lesions at one year. Radiofrequency energy was utilised in all patients, with a median application time of 2.67 minutes. Median procedure time was found to be 55.5 minutes and fluoroscopy median of 3.5 minutes. Median radiation dose was 11 mGy. We found no acute or subacute complications up to three months. In conclusion, our right-sided approach for ablation, staged post-device insertion demonstrated results in keeping with other centres in the UK and Europe. We expect our current practice to become more widespread, given the increased risk of lead-related complications or failures associated with physiological pacing compared with standard pacing methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.